Enter your login e-mail to the account
Search
Search parameters
Search results
- Impact of CDK 4/6 inhibitors on overall survival of patients with advanced breast cancer – in the light of new data
MUDr. Bibiána Vertáková Krakovská, PhD.
(2/2024, Company information ) - Treatment of HR+, HER2- advanced/metastatic breast cancer according to ESO-ESMO recommendations ABC 5
MUDr. Soňa Johnová, MUDr. Soňa Huľová
(2/2021, Review articles ) - Management of adverse reactions in treatment with mTOR and CDK4/6 inhibitors
MUDr. Branislav Bystrický, PhD., MPH
(2/2019, Review articles ) - Position of 4/6 cyclin-dependent kinase inhibitors in the 1st line of treatment of metastatic breast cancer
MUDr. Katarína Krajcsovics, PhD.
(4/2019, Review articles ) - Nové perspektívy v liečbe pokročilého a metastatického HR+ HER2- karcinómu prsníka
MUDr. Miroslava Malejčíková, MUDr. Silvia Jurišová
(2/2018, Review articles ) - Optimal management of patients with breast cancer after progression on CDK4/6 inhibitors.
MUDr. Filip Kohútek, PhD., MUDr. Branislav Bystrický, PhD., MPH
(2/2022, Main topic ) - How do we look at CDK4/6 inhibitors in palliative treatment today
MUDr. Miroslava Malejčíková
(2/2022, Main topic ) - Ribociclib, inhibitor of cyclin-dependent kinases 4 and 6, in the treatment of HR+/HER2 - advanced breast cancer
MUDr. Mária Rečková
(1/2017, Drugs & drug classes ) - Palbociclib in the treatment of advanced breast cancer
MUDr. Branislav Bystrický
(1/2017, Drugs & drug classes ) - Abemaciclib in first-line treatment of HR+, HER2- breast cancer with visceral metastases in a premenopausal patient
MUDr. Soňa Johnová, MUDr. Soňa Huľová
(3/2022, Case reports )